Brief: Compass Pathways Successfully Achieves Primary Endpoint In Second Phase 3 Trial Evaluating Comp360 Psilocybin
17/02/2026 11:43
Feb 17 (Reuters) - Compass Pathways PLC CMPS.O: COMPASS PATHWAYS SUCCESSFULLY ACHIEVES PRIMARY ENDPOINT IN SECOND PHASE 3 TRIAL EVALUATING COMP360 PSILOCYBIN FOR TREATMENT-RESISTANT DEPRESSION COMPASS PATHWAYS PLC - COMP360 SHOWS WELL-TOLERATED AND SAFE PROFILE COMPASS PATHWAYS PLC - REQUESTS FDA MEETING FOR ROLLING SUBMISSION Source text: ID:nBw6fCmxZa Further company coverage: CMPS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on COMPASS Pathways
See all newsCompass Pathways PLC reports results for the quarter ended September 30 - Earnings Summary
Corrected: Compass Pathways Q3 net loss narrows on lower R&D charges
Corrected: BRIEF-COMPASS Pathways Q3 EPS USD -0.31
Psychedelic drug developers fall after Usona submits depressive drug application
Compass Pathways PLC expected to post a loss of 45 cents a share - Earnings Preview